Business
Omnicell provides medication-management automation and software.
Omnicell grew revenue, remained profitable, generated positive free cash flow at a 0.4% operating margin. Net income and operating margin were near break-even, and cash conversion weakened as investment rose.
The read at a glance✓ Audited against SEC data
- Growth — Revenue grew 6.5%OK
- Profitability — Net income declined 83.6% to $2.052M from $12.531MWatch
- Cash flow — Free cash flow declined 42.6% to $86.885M from $151.259MWatch
- Margins — Operating margin expanded 41 bps to 0.44%OK
- Accounting — Net income and operating margin were near break-even, and cash conversion weakened as investment roseNote
- Insiders — 0 purchases and 10 salesWatch
Where the revenue comes from
Fiscal 2025, as OMNICELL, INC. reports it. History and quarterly detail are in the app.
- Product revenues$665.7M
- Connected devices, software licenses, and other$565.5M
- Service revenues$519.1M
- Technical services$260.1M
- SaaS and Expert Services$259.1M
Leadership changes
From OMNICELL, INC.'s own filings, the day they're filed.
- Nchacha Etta · Chief Financial Officer · departureeff. 2025-11-15
- Nchacha Etta · Chief Financial Officer · departureeff. 2025-09-15
- Nchacha Etta · Chief Financial Officer · departureeff. 2025-09-15
Latest filings
- 10-Q · Quarterly report2026-08-05
- 8-K · Company announcement2026-07-30
- 8-K · Company announcement2026-07-01
- 8-K · Company announcement2026-05-26
- 10-Q · Quarterly report2026-05-06
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about OMNICELL, INC., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.